CCL17 Recombinant Monoclonal Antibody

說明書

中文名稱：

CCL17 Recombinant Monoclonal Antibody
貨號：

CSB-RA856406MA1HU
規格：

￥1320
圖片：
The Binding Activity of Human CCL17 with Anti-CCL17 recombinant antibody
Activity: Measured by its binding ability in a functional ELISA. Immobilized Anti-CCL17 recombinant antibody at 2 μg/mL can bind Human CCL17 protein (CSB-MP856406HU) . The EC₅₀ is 2.403-2.741 ng/mL.

The Binding Activity of Macaca mulatta CCL17 with Anti-CCL17 recombinant antibody
Activity: Measured by its binding ability in a functional ELISA. Immobilized Anti-CCL17 recombinant antibody at 2 μg/mL can bind Mouse Ccl17 protein (CSB-MP6512MO). The EC₅₀ is 0.9792-1.486 ng/mL.

The Binding Activity of Macaca mulatta CCL17 with Anti-CCL17 recombinant antibody
Activity: Measured by its binding ability in a functional ELISA. Immobilized Anti-CCL17 recombinant antibody at 2 μg/mL can bind Macaca mulatta CCL17 protein (CSB-MP811562MOW). The EC₅₀ is 1.953-2.469 ng/mL.

Overlay Peak curve showing Raji cells stained with CSB-RA856406MA1HU (red line) at 1:100. The cells were fixed in 4% formaldehyde and permeated by 0.2% TritonX-100 for 10min. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1ug/1*10⁶cells) for 45min at 4℃. The secondary antibody used was Fluorescein (FITC) AffiniPure Goat Anti-Human IgG, Fcγ fragment specific at 1:200 dilution for 35 min at 4℃.Control antibody (green line) was human IgG1 (1ug/1*10⁶cells) used under the same conditions. Acquisition of >10,000 events was performed.
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

Uniprot No.：

Q92583
基因名：

CCL17
別名：

A-152E5.3 antibody; A152E53 antibody; ABCD 2 antibody; ABCD2 antibody; C-C motif chemokine 17 antibody; CC chemokine TARC antibody; CCL17 antibody; CCL17_HUMAN antibody; Chemokine CC Motif Ligand 17 antibody; MGC138271 antibody; MGC138273 antibody; SCYA17 antibody; Small Inducible Cytokine A17 antibody; Small Inducible Cytokine A17 Precursor antibody; Small Inducible Cytokine Subfamily A (Cys Cys) antibody; Small Inducible Cytokine Subfamily A (Cys Cys) Member 17 antibody; Small-inducible cytokine A17 antibody; T Cell Directed CC Chemokine antibody; Thymus and activation regulated chemokine antibody; Thymus and activation-regulated chemokine antibody
反應種屬：

Human, Mouse, Macaca fascicularis
免疫原：

Recombinant Human CCL17 protein
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
克隆類型：

Monoclonal
抗體亞型：

hIgG2
純化方式：

Affinity-chromatography
克隆號：

7D3
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產品提供形式：

Liquid
應用范圍：

ELISA, FC

推薦稀釋比：

Application	Recommended Dilution
ELISA	1:5000-1:50000
FC	1:50-1:200

Protocols：

ELISA Protocol
Flow cytometry (FC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Chemotactic factor for T-lymphocytes but not monocytes or granulocytes. May play a role in T-cell development in thymus and in trafficking and activation of mature T-cells. Binds to CCR4.
基因功能參考文獻：
1. The frequency of the CC genotype in the TARC rs223828 SNP was higher in patients with intractable Graves disease than in patients with Graves disease in remission. PMID: 29848886
2. The expression of CCL17 was decreased in nasal polyp (NP) epithelium compared to the epithelium of normal ethmoid sinus, whereas the expression of CCL22 was not decreased. E-cadherin was differentially distributed between the epithelium of normal ethmoid sinus and NP epithelium. EGFR was also decreased in NPs. PMID: 29746583
3. TARC serum levels were elevated in 78% of sarcoidosis patients and correlated with disease severity. PMID: 29598931
4. Serum TARC level may be a potent marker reflecting better response to IL-17A inhibitors for psoriasis treatment. PMID: 29655215
5. This review presents key clinical studies of Multiple sclerosis together with experimental studies in animals that have demonstrated functional roles of CCR4, CCL17, and CCL22 in experimental autoimmune encephalomyelitis pathogenesis. [review] PMID: 29099057
6. Taken together, our data showed a likely positive feedback mechanism of enhanced IL-6 production in ectopic milieu. The high levels of IL-6 in the peritoneal cavity stimulate the expression of CCL17 in endometrial stromal cells by activating JNK signal pathway, and then, CCL17 further induces CCR4 expression on macrophages, which eventually leads to an increase in IL-6 production via NF-kappaB activation. PMID: 28240436
7. Data suggest that high levels of CCL17 and CCL22 in endometrium in women with endometriosis promote (1) recruitment of Tregs, (2) immunosuppression of Tregs, and (3) angiogenesis in endometrium. (Tregs = regulatory T cells) PMID: 28383711
8. Serum TARC levels correlate well with indicators of systemic inflammation and of disease severity among patients with a drug eruption except SJS/TEN. Serum TARC may be a prognostic biomarker of severity of inflammation in drug eruptions. PMID: 28648978
9. TARC production in HaCaT keratinocytes through the interaction between IL-22 and IL-22Ralpha facilitates T-cell migration in atopic dermatitis caused by house dust mites. PMID: 26914146
10. TARC is a candidate biomarker for PTSD only in males. PMID: 28170001
11. High CCL17 expression is associated with colon cancer cell migration. PMID: 28146427
12. GM-CSF can mediate inflammation and pain by regulating IRF4-induced CCL17 production PMID: 27525438
13. Based on the ADEPT study data set, we report that airway mucosal expression of CCL26 was a robust discriminator of type 2 inflammation from healthy nonatopic subjects. Furthermore, airway mucosal CCL26 expression was best identified by using a panel of clinical biomarkers, including Feno values, bEOS counts, and expression of 2 novel markers, sCCL17 and sCCL26 PMID: 28089872
14. Low CCL17 expression is a potential independent adverse prognostic biomarker for recurrence and survival of patients with clear cell renal cell carcinoma after nephrectomy. PMID: 28178948
15. IP-10 serum increase or TARC/IP-10 ratio decrease along with abnormal hepatic enzymatic alteration could signify early rejection of the transplanted liver. PMID: 28245475
16. elevated pre-treatment levels of sGal-1, sCD163, sCD30 and TARC can be found in patients with classic Hodgkin lymphoma. However, only plasma TARC accurately reflects disease activity and correlates with clinical treatment response. PMID: 27610595
17. levels elevated in rheumatoid arthritis synovial fluid, due to production by mononuclear cells, particularly CD1c classical dendritic cells PMID: 27250804
18. Serum TARC levels are well correlated with blood eosinophil counts in patients with generalized drug eruptions, indicating that Th2-type immune reactions underlie TARC production. Serum TARC measurements also have potent diagnostic value for DIHS, with high sensitivity and specificity. PMID: 27497618
19. Data suggest that Th1 (IFN-gamma-inducible protein-10 IP-10/CXCL10) and Th2 (thymus and activation regulated chemokine TARC/CCL17) and (macrophage derived chemokine MDC/CCL22) cooperatively play a role in the development of ankylosing spondylitis (AS). PMID: 26827189
20. CCL17 positively regulates the tumorigenesis of hepatocellular carcinoma.Higher levels of intratumoral CCL17 expression are associated with poorer survival of hepatocellular carcinoma patients. PMID: 26781124
21. CCL17 and CCL18 dermal expression is associated with leprosy polarity. PMID: 25412496
22. The SNP rs223895 in TARC/CCL17 gene is associated with the susceptibility to Kawasaki disease. PMID: 26182268
23. Serum CCL17 levels are associated with coronary artery disease and atherosclerosis severity independently of traditional cardiovascular risk factors. PMID: 25555269
24. TARC was correlated with disease status and its monitoring may be able to predict PET positivity after alloSCT, thus potentially allowing an early immune manipulation. PMID: 25240818
25. Serum levels of CCL17 were positively correlated with coronary artery disease. PMID: 25062565
26. increased expression in the thymus of myasthenia gravis patients PMID: 24397961
27. TARC and interleukin-31 may be biomarkers for adult atopic dermatitis PMID: 24984931
28. Serum TARC is a promising biomarker for remission and can be used for accurately monitoring proactive treatment for long-term control. [revew] PMID: 24628072
29. disease activity and response biomarker in alopecia areata PMID: 24102731
30. High CXCL10 levels were detected in acutely infected children regardless of virus pathogen, whereas increased CCL17 production was RSV-specific PMID: 25013801
31. Higher serum concentrations of CCL17 at baseline may be predictive of acute exacerbations in patients with chronic hypersensitivity pneumonitis PMID: 23705860
32. might be potential marker of non-eosinophilic oesophagitis gastrointestinal food allergies PMID: 24698291
33. Serum TARC may represent a suitable biomarker for monitoring of atopic dermatitis severity in daily practice. PMID: 25199679
34. Although TARC and I-TAC may not directly regulate pruritus in atopic dermatitis patients, these chemokines are very sensitive disease markers of AD. PMID: 24104601
35. we found that TARC is an easily measured biomarker that is associated with faster TTR, longer PFS, and possibly longer OS in a population of patients with HL who were treated with panobinostat. PMID: 23822537
36. The serum TARC level is a very sensitive biomarker for monitoring the severity and treatment response in AD PMID: 25268342
37. CCL17 is an antimicrobial protein with bacteriocidal activity against E. coli and S. aureus. PMID: 12949249
38. An association between TARC/CCL17 polymorphisms, susceptibility of Kawasaki disease, and intravenous immunoglobulin responses in Kawasaki disease patients. PMID: 23942559
39. Migration assays were performed to evaluate CCL17-induced colon cancer cell (HT-29) chemotaxis and RhoA protein levels were quantified. PMID: 24582560
40. Ginseng inhibited TARC expression via blockade of NF-kappaB activation in HaCaT cells. PMID: 23454147
41. CCL17-induced, CCR4-dependent release of CGRP by human airway epithelial cells represents a novel inflammatory pathway in patients with asthma and allergic disease. PMID: 23731651
42. These data reveal an elevated serum concentration of Th2-attracting chemokines CCL22 and CCL17 in opsoclonus-myoclonus syndrome. PMID: 23340773
43. Autistic children had significantly higher serum levels of TARC than healthy controls PMID: 23782855
44. Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma. PMID: 23224400
45. Data suggest an important role for serum CCL17 level as biomarker of drug resistance/remission induction in Hodgkin lymphoma in response to various combined neoplastic agent protocols. PMID: 23225085
46. increased expression in macrophages from asthmatic patients PMID: 22981793
47. Data show that PD-1, PD-L1, PD-L2, CCL17, and CCL22 mRNA was identified in papillomas. PMID: 22322668
48. Serum concentrations of TARC and CTACK were significantly higher in AD (atopic dermatitis) children than in healthy controls, and correlated with severity of symptoms. PMID: 22017510
49. Baseline plasma thymus and activation-regulated chemokine levels correlate with classical Hodgkin's lymphoma tumor burden and serial levels correlate with response to treatment in patients with classical Hodgkin's lymphoma. PMID: 22058214
50. PI16-positive Treg showed enhanced in vitro migration towards the inflammatory chemokines CCL17 and CCL20, suggesting they can migrate to sites of inflammation PMID: 22533972
顯示更多

收起更多
亞細胞定位：

Secreted.
蛋白家族：

Intercrine beta (chemokine CC) family
組織特異性：

Expressed at high levels in thymus and at low levels in the lung, colon and small intestine.
數據庫鏈接：

HGNC: 10615

OMIM: 601520

KEGG: hsa:6361

STRING: 9606.ENSP00000219244

UniGene: Hs.546294

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human